nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B3—Olmesartan—coronary artery disease	0.038	0.0551	CbGbCtD
Dabrafenib—SLCO1B3—Pitavastatin—coronary artery disease	0.0304	0.0441	CbGbCtD
Dabrafenib—SLCO1B3—Telmisartan—coronary artery disease	0.0304	0.0441	CbGbCtD
Dabrafenib—SLCO1B3—Valsartan—coronary artery disease	0.0296	0.0429	CbGbCtD
Dabrafenib—SLCO1B1—Gemfibrozil—coronary artery disease	0.0234	0.0339	CbGbCtD
Dabrafenib—SLCO1B3—Rosuvastatin—coronary artery disease	0.0224	0.0325	CbGbCtD
Dabrafenib—SLCO1B1—Olmesartan—coronary artery disease	0.0222	0.0321	CbGbCtD
Dabrafenib—SLCO1B3—Pravastatin—coronary artery disease	0.0204	0.0296	CbGbCtD
Dabrafenib—SLCO1B3—Atorvastatin—coronary artery disease	0.0186	0.0269	CbGbCtD
Dabrafenib—SLCO1B1—Pitavastatin—coronary artery disease	0.0177	0.0257	CbGbCtD
Dabrafenib—SLCO1B1—Valsartan—coronary artery disease	0.0172	0.025	CbGbCtD
Dabrafenib—SLCO1B3—Losartan—coronary artery disease	0.017	0.0246	CbGbCtD
Dabrafenib—SLC22A8—Enalapril—coronary artery disease	0.0155	0.0225	CbGbCtD
Dabrafenib—ABCG2—Pitavastatin—coronary artery disease	0.0141	0.0204	CbGbCtD
Dabrafenib—ABCG2—Telmisartan—coronary artery disease	0.0141	0.0204	CbGbCtD
Dabrafenib—SLCO1B1—Ezetimibe—coronary artery disease	0.0131	0.0189	CbGbCtD
Dabrafenib—SLCO1B1—Rosuvastatin—coronary artery disease	0.0131	0.0189	CbGbCtD
Dabrafenib—CYP2C8—Fenofibrate—coronary artery disease	0.0124	0.0179	CbGbCtD
Dabrafenib—SLCO1B1—Simvastatin—coronary artery disease	0.0121	0.0176	CbGbCtD
Dabrafenib—SLCO1B1—Pravastatin—coronary artery disease	0.0119	0.0172	CbGbCtD
Dabrafenib—SLCO1B1—Lovastatin—coronary artery disease	0.0119	0.0172	CbGbCtD
Dabrafenib—SLC22A8—Pravastatin—coronary artery disease	0.011	0.0159	CbGbCtD
Dabrafenib—SLCO1B1—Atorvastatin—coronary artery disease	0.0108	0.0157	CbGbCtD
Dabrafenib—SLC22A6—Enalapril—coronary artery disease	0.0108	0.0156	CbGbCtD
Dabrafenib—ABCG2—Rosuvastatin—coronary artery disease	0.0104	0.015	CbGbCtD
Dabrafenib—ABCG2—Ezetimibe—coronary artery disease	0.0104	0.015	CbGbCtD
Dabrafenib—SLCO1B1—Losartan—coronary artery disease	0.00989	0.0143	CbGbCtD
Dabrafenib—CYP2C8—Gemfibrozil—coronary artery disease	0.00989	0.0143	CbGbCtD
Dabrafenib—ABCG2—Pravastatin—coronary artery disease	0.00944	0.0137	CbGbCtD
Dabrafenib—ABCB1—Ticagrelor—coronary artery disease	0.00939	0.0136	CbGbCtD
Dabrafenib—SLC22A8—Furosemide—coronary artery disease	0.00932	0.0135	CbGbCtD
Dabrafenib—CYP2C8—Clopidogrel—coronary artery disease	0.00857	0.0124	CbGbCtD
Dabrafenib—SLC22A6—Acetylsalicylic acid—coronary artery disease	0.00818	0.0119	CbGbCtD
Dabrafenib—SLC22A6—Captopril—coronary artery disease	0.00808	0.0117	CbGbCtD
Dabrafenib—SLC22A6—Pravastatin—coronary artery disease	0.00764	0.0111	CbGbCtD
Dabrafenib—CYP2C8—Pitavastatin—coronary artery disease	0.00749	0.0109	CbGbCtD
Dabrafenib—SLC22A6—Furosemide—coronary artery disease	0.00649	0.00941	CbGbCtD
Dabrafenib—SLC22A6—Losartan—coronary artery disease	0.00636	0.00922	CbGbCtD
Dabrafenib—ABCB1—Clopidogrel—coronary artery disease	0.0058	0.00841	CbGbCtD
Dabrafenib—ABCB1—Perindopril—coronary artery disease	0.0058	0.00841	CbGbCtD
Dabrafenib—CYP3A4—Ticagrelor—coronary artery disease	0.00563	0.00816	CbGbCtD
Dabrafenib—CYP2C8—Acetylsalicylic acid—coronary artery disease	0.00538	0.00781	CbGbCtD
Dabrafenib—CYP2C8—Simvastatin—coronary artery disease	0.00514	0.00745	CbGbCtD
Dabrafenib—ABCB1—Telmisartan—coronary artery disease	0.00507	0.00735	CbGbCtD
Dabrafenib—ABCB1—Pitavastatin—coronary artery disease	0.00507	0.00735	CbGbCtD
Dabrafenib—CYP2C8—Pravastatin—coronary artery disease	0.00503	0.00729	CbGbCtD
Dabrafenib—CYP2C8—Lovastatin—coronary artery disease	0.00503	0.00729	CbGbCtD
Dabrafenib—CYP3A4—Fenofibrate—coronary artery disease	0.00502	0.00727	CbGbCtD
Dabrafenib—ABCB1—Lisinopril—coronary artery disease	0.00481	0.00697	CbGbCtD
Dabrafenib—ABCB1—Enalapril—coronary artery disease	0.00481	0.00697	CbGbCtD
Dabrafenib—CYP2C8—Atorvastatin—coronary artery disease	0.00458	0.00664	CbGbCtD
Dabrafenib—CYP2C8—Losartan—coronary artery disease	0.00419	0.00607	CbGbCtD
Dabrafenib—ABCB1—Timolol—coronary artery disease	0.00409	0.00593	CbGbCtD
Dabrafenib—CYP3A4—Gemfibrozil—coronary artery disease	0.00401	0.00581	CbGbCtD
Dabrafenib—ABCB1—Ezetimibe—coronary artery disease	0.00374	0.00542	CbGbCtD
Dabrafenib—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00364	0.00528	CbGbCtD
Dabrafenib—ABCB1—Captopril—coronary artery disease	0.0036	0.00522	CbGbCtD
Dabrafenib—CYP3A4—Clopidogrel—coronary artery disease	0.00348	0.00504	CbGbCtD
Dabrafenib—ABCB1—Simvastatin—coronary artery disease	0.00348	0.00504	CbGbCtD
Dabrafenib—ABCB1—Lovastatin—coronary artery disease	0.0034	0.00493	CbGbCtD
Dabrafenib—ABCB1—Pravastatin—coronary artery disease	0.0034	0.00493	CbGbCtD
Dabrafenib—CYP3A4—Eplerenone—coronary artery disease	0.00323	0.00469	CbGbCtD
Dabrafenib—ABCB1—Atorvastatin—coronary artery disease	0.0031	0.00449	CbGbCtD
Dabrafenib—CYP3A4—Enalapril—coronary artery disease	0.00288	0.00418	CbGbCtD
Dabrafenib—ABCB1—Losartan—coronary artery disease	0.00283	0.00411	CbGbCtD
Dabrafenib—CYP3A4—Rosuvastatin—coronary artery disease	0.00224	0.00325	CbGbCtD
Dabrafenib—CYP3A4—Ezetimibe—coronary artery disease	0.00224	0.00325	CbGbCtD
Dabrafenib—CYP3A4—Simvastatin—coronary artery disease	0.00208	0.00302	CbGbCtD
Dabrafenib—CYP3A4—Lovastatin—coronary artery disease	0.00204	0.00296	CbGbCtD
Dabrafenib—CYP3A4—Pravastatin—coronary artery disease	0.00204	0.00296	CbGbCtD
Dabrafenib—CYP3A4—Atorvastatin—coronary artery disease	0.00186	0.00269	CbGbCtD
Dabrafenib—CYP3A4—Losartan—coronary artery disease	0.0017	0.00246	CbGbCtD
Dabrafenib—LIMK1—heart—coronary artery disease	0.00131	0.105	CbGeAlD
Dabrafenib—SIK1—cardiac ventricle—coronary artery disease	0.00103	0.0827	CbGeAlD
Dabrafenib—LIMK1—blood—coronary artery disease	0.000974	0.0783	CbGeAlD
Dabrafenib—SIK1—myocardium—coronary artery disease	0.000967	0.0778	CbGeAlD
Dabrafenib—RAF1—cardiac ventricle—coronary artery disease	0.000819	0.0658	CbGeAlD
Dabrafenib—BRAF—heart—coronary artery disease	0.000807	0.0649	CbGeAlD
Dabrafenib—RAF1—myocardium—coronary artery disease	0.00077	0.0619	CbGeAlD
Dabrafenib—SIK1—heart—coronary artery disease	0.000675	0.0543	CbGeAlD
Dabrafenib—BRAF—blood—coronary artery disease	0.000602	0.0484	CbGeAlD
Dabrafenib—SIK1—cardiac atrium—coronary artery disease	0.000578	0.0464	CbGeAlD
Dabrafenib—RAF1—heart—coronary artery disease	0.000537	0.0432	CbGeAlD
Dabrafenib—RAF1—cardiovascular system—coronary artery disease	0.000507	0.0408	CbGeAlD
Dabrafenib—SIK1—blood—coronary artery disease	0.000504	0.0405	CbGeAlD
Dabrafenib—RAF1—cardiac atrium—coronary artery disease	0.00046	0.037	CbGeAlD
Dabrafenib—RAF1—blood—coronary artery disease	0.000401	0.0322	CbGeAlD
Dabrafenib—SLCO1B1—blood—coronary artery disease	0.0003	0.0241	CbGeAlD
Dabrafenib—SLC22A8—blood—coronary artery disease	0.000233	0.0187	CbGeAlD
Dabrafenib—ABCG2—heart—coronary artery disease	0.000222	0.0179	CbGeAlD
Dabrafenib—CYP2C8—blood—coronary artery disease	0.000171	0.0137	CbGeAlD
Dabrafenib—ABCG2—blood—coronary artery disease	0.000166	0.0133	CbGeAlD
Dabrafenib—CYP3A4—blood—coronary artery disease	0.000116	0.00929	CbGeAlD
Dabrafenib—ABCB1—heart—coronary artery disease	0.00011	0.00881	CbGeAlD
Dabrafenib—ABCB1—cardiovascular system—coronary artery disease	0.000103	0.00832	CbGeAlD
Dabrafenib—ABCB1—blood—coronary artery disease	8.18e-05	0.00658	CbGeAlD
Dabrafenib—Dermatitis—Fenofibrate—coronary artery disease	6.91e-05	0.000415	CcSEcCtD
Dabrafenib—Decreased appetite—Furosemide—coronary artery disease	6.89e-05	0.000414	CcSEcCtD
Dabrafenib—Headache—Fenofibrate—coronary artery disease	6.87e-05	0.000412	CcSEcCtD
Dabrafenib—Vision blurred—Lisinopril—coronary artery disease	6.87e-05	0.000412	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Captopril—coronary artery disease	6.87e-05	0.000412	CcSEcCtD
Dabrafenib—Cough—Timolol—coronary artery disease	6.86e-05	0.000412	CcSEcCtD
Dabrafenib—Vomiting—Clopidogrel—coronary artery disease	6.86e-05	0.000411	CcSEcCtD
Dabrafenib—Diarrhoea—Simvastatin—coronary artery disease	6.86e-05	0.000411	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Furosemide—coronary artery disease	6.85e-05	0.000411	CcSEcCtD
Dabrafenib—Arthralgia—Ramipril—coronary artery disease	6.84e-05	0.000411	CcSEcCtD
Dabrafenib—Myalgia—Ramipril—coronary artery disease	6.84e-05	0.000411	CcSEcCtD
Dabrafenib—Fatigue—Furosemide—coronary artery disease	6.84e-05	0.00041	CcSEcCtD
Dabrafenib—Abdominal pain—Telmisartan—coronary artery disease	6.83e-05	0.00041	CcSEcCtD
Dabrafenib—Body temperature increased—Telmisartan—coronary artery disease	6.83e-05	0.00041	CcSEcCtD
Dabrafenib—Vomiting—Lovastatin—coronary artery disease	6.81e-05	0.000409	CcSEcCtD
Dabrafenib—Dizziness—Eplerenone—coronary artery disease	6.8e-05	0.000408	CcSEcCtD
Dabrafenib—Rash—Clopidogrel—coronary artery disease	6.8e-05	0.000408	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	6.8e-05	0.000408	CcSEcCtD
Dabrafenib—Dermatitis—Clopidogrel—coronary artery disease	6.79e-05	0.000408	CcSEcCtD
Dabrafenib—Asthenia—Valsartan—coronary artery disease	6.79e-05	0.000407	CcSEcCtD
Dabrafenib—Hypertension—Timolol—coronary artery disease	6.79e-05	0.000407	CcSEcCtD
Dabrafenib—Constipation—Furosemide—coronary artery disease	6.78e-05	0.000407	CcSEcCtD
Dabrafenib—Hypersensitivity—Niacin—coronary artery disease	6.78e-05	0.000407	CcSEcCtD
Dabrafenib—Asthenia—Olmesartan—coronary artery disease	6.76e-05	0.000405	CcSEcCtD
Dabrafenib—Headache—Clopidogrel—coronary artery disease	6.76e-05	0.000405	CcSEcCtD
Dabrafenib—Rash—Lovastatin—coronary artery disease	6.75e-05	0.000405	CcSEcCtD
Dabrafenib—Dermatitis—Lovastatin—coronary artery disease	6.75e-05	0.000405	CcSEcCtD
Dabrafenib—Anaemia—Lisinopril—coronary artery disease	6.74e-05	0.000404	CcSEcCtD
Dabrafenib—Headache—Lovastatin—coronary artery disease	6.71e-05	0.000403	CcSEcCtD
Dabrafenib—Pruritus—Valsartan—coronary artery disease	6.69e-05	0.000402	CcSEcCtD
Dabrafenib—Dry mouth—Ramipril—coronary artery disease	6.69e-05	0.000402	CcSEcCtD
Dabrafenib—Arthralgia—Timolol—coronary artery disease	6.69e-05	0.000401	CcSEcCtD
Dabrafenib—Myalgia—Timolol—coronary artery disease	6.69e-05	0.000401	CcSEcCtD
Dabrafenib—Vomiting—Ezetimibe—coronary artery disease	6.68e-05	0.000401	CcSEcCtD
Dabrafenib—Hypersensitivity—Pravastatin—coronary artery disease	6.67e-05	0.0004	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Perindopril—coronary artery disease	6.67e-05	0.0004	CcSEcCtD
Dabrafenib—Pruritus—Olmesartan—coronary artery disease	6.66e-05	0.0004	CcSEcCtD
Dabrafenib—Decreased appetite—Losartan—coronary artery disease	6.65e-05	0.000399	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	6.65e-05	0.000399	CcSEcCtD
Dabrafenib—Abdominal pain—Captopril—coronary artery disease	6.64e-05	0.000399	CcSEcCtD
Dabrafenib—Body temperature increased—Captopril—coronary artery disease	6.64e-05	0.000399	CcSEcCtD
Dabrafenib—Dizziness—Simvastatin—coronary artery disease	6.63e-05	0.000398	CcSEcCtD
Dabrafenib—Rash—Ezetimibe—coronary artery disease	6.62e-05	0.000397	CcSEcCtD
Dabrafenib—Dermatitis—Ezetimibe—coronary artery disease	6.62e-05	0.000397	CcSEcCtD
Dabrafenib—Asthenia—Niacin—coronary artery disease	6.6e-05	0.000396	CcSEcCtD
Dabrafenib—Fatigue—Losartan—coronary artery disease	6.6e-05	0.000396	CcSEcCtD
Dabrafenib—Headache—Ezetimibe—coronary artery disease	6.58e-05	0.000395	CcSEcCtD
Dabrafenib—Oedema—Ramipril—coronary artery disease	6.56e-05	0.000394	CcSEcCtD
Dabrafenib—Dry mouth—Timolol—coronary artery disease	6.54e-05	0.000393	CcSEcCtD
Dabrafenib—Constipation—Losartan—coronary artery disease	6.54e-05	0.000393	CcSEcCtD
Dabrafenib—Vomiting—Eplerenone—coronary artery disease	6.54e-05	0.000392	CcSEcCtD
Dabrafenib—Leukopenia—Lisinopril—coronary artery disease	6.53e-05	0.000392	CcSEcCtD
Dabrafenib—Nausea—Fenofibrate—coronary artery disease	6.52e-05	0.000391	CcSEcCtD
Dabrafenib—Pruritus—Niacin—coronary artery disease	6.51e-05	0.000391	CcSEcCtD
Dabrafenib—Asthenia—Pravastatin—coronary artery disease	6.5e-05	0.00039	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Furosemide—coronary artery disease	6.49e-05	0.000389	CcSEcCtD
Dabrafenib—Rash—Eplerenone—coronary artery disease	6.48e-05	0.000389	CcSEcCtD
Dabrafenib—Hypersensitivity—Trandolapril—coronary artery disease	6.48e-05	0.000389	CcSEcCtD
Dabrafenib—Dermatitis—Eplerenone—coronary artery disease	6.48e-05	0.000389	CcSEcCtD
Dabrafenib—Diarrhoea—Valsartan—coronary artery disease	6.47e-05	0.000388	CcSEcCtD
Dabrafenib—Hypersensitivity—Enalapril—coronary artery disease	6.45e-05	0.000387	CcSEcCtD
Dabrafenib—Abdominal pain—Perindopril—coronary artery disease	6.45e-05	0.000387	CcSEcCtD
Dabrafenib—Body temperature increased—Perindopril—coronary artery disease	6.45e-05	0.000387	CcSEcCtD
Dabrafenib—Diarrhoea—Olmesartan—coronary artery disease	6.44e-05	0.000387	CcSEcCtD
Dabrafenib—Headache—Eplerenone—coronary artery disease	6.44e-05	0.000387	CcSEcCtD
Dabrafenib—Nervous system disorder—Ramipril—coronary artery disease	6.43e-05	0.000386	CcSEcCtD
Dabrafenib—Thrombocytopenia—Ramipril—coronary artery disease	6.42e-05	0.000385	CcSEcCtD
Dabrafenib—Oedema—Timolol—coronary artery disease	6.41e-05	0.000385	CcSEcCtD
Dabrafenib—Pruritus—Pravastatin—coronary artery disease	6.41e-05	0.000385	CcSEcCtD
Dabrafenib—Nausea—Clopidogrel—coronary artery disease	6.41e-05	0.000384	CcSEcCtD
Dabrafenib—Skin disorder—Ramipril—coronary artery disease	6.37e-05	0.000382	CcSEcCtD
Dabrafenib—Infection—Timolol—coronary artery disease	6.37e-05	0.000382	CcSEcCtD
Dabrafenib—Vomiting—Simvastatin—coronary artery disease	6.37e-05	0.000382	CcSEcCtD
Dabrafenib—Hypersensitivity—Telmisartan—coronary artery disease	6.37e-05	0.000382	CcSEcCtD
Dabrafenib—Cough—Lisinopril—coronary artery disease	6.36e-05	0.000382	CcSEcCtD
Dabrafenib—Nausea—Lovastatin—coronary artery disease	6.36e-05	0.000382	CcSEcCtD
Dabrafenib—Hyperhidrosis—Ramipril—coronary artery disease	6.34e-05	0.000381	CcSEcCtD
Dabrafenib—Rash—Simvastatin—coronary artery disease	6.32e-05	0.000379	CcSEcCtD
Dabrafenib—Dermatitis—Simvastatin—coronary artery disease	6.31e-05	0.000379	CcSEcCtD
Dabrafenib—Asthenia—Trandolapril—coronary artery disease	6.31e-05	0.000379	CcSEcCtD
Dabrafenib—Diarrhoea—Niacin—coronary artery disease	6.29e-05	0.000378	CcSEcCtD
Dabrafenib—Nervous system disorder—Timolol—coronary artery disease	6.29e-05	0.000377	CcSEcCtD
Dabrafenib—Asthenia—Enalapril—coronary artery disease	6.29e-05	0.000377	CcSEcCtD
Dabrafenib—Headache—Simvastatin—coronary artery disease	6.28e-05	0.000377	CcSEcCtD
Dabrafenib—Body temperature increased—Furosemide—coronary artery disease	6.27e-05	0.000376	CcSEcCtD
Dabrafenib—Abdominal pain—Furosemide—coronary artery disease	6.27e-05	0.000376	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Losartan—coronary artery disease	6.26e-05	0.000375	CcSEcCtD
Dabrafenib—Dizziness—Valsartan—coronary artery disease	6.26e-05	0.000375	CcSEcCtD
Dabrafenib—Nausea—Ezetimibe—coronary artery disease	6.24e-05	0.000374	CcSEcCtD
Dabrafenib—Skin disorder—Timolol—coronary artery disease	6.23e-05	0.000374	CcSEcCtD
Dabrafenib—Dizziness—Olmesartan—coronary artery disease	6.23e-05	0.000374	CcSEcCtD
Dabrafenib—Pruritus—Trandolapril—coronary artery disease	6.22e-05	0.000373	CcSEcCtD
Dabrafenib—Arthralgia—Lisinopril—coronary artery disease	6.21e-05	0.000372	CcSEcCtD
Dabrafenib—Myalgia—Lisinopril—coronary artery disease	6.21e-05	0.000372	CcSEcCtD
Dabrafenib—Hyperhidrosis—Timolol—coronary artery disease	6.2e-05	0.000372	CcSEcCtD
Dabrafenib—Asthenia—Telmisartan—coronary artery disease	6.2e-05	0.000372	CcSEcCtD
Dabrafenib—Pruritus—Enalapril—coronary artery disease	6.2e-05	0.000372	CcSEcCtD
Dabrafenib—Diarrhoea—Pravastatin—coronary artery disease	6.2e-05	0.000372	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	6.16e-05	0.00037	CcSEcCtD
Dabrafenib—Hypotension—Ramipril—coronary artery disease	6.13e-05	0.000368	CcSEcCtD
Dabrafenib—Pruritus—Telmisartan—coronary artery disease	6.11e-05	0.000367	CcSEcCtD
Dabrafenib—Nausea—Eplerenone—coronary artery disease	6.11e-05	0.000366	CcSEcCtD
Dabrafenib—Dizziness—Niacin—coronary artery disease	6.08e-05	0.000365	CcSEcCtD
Dabrafenib—Dry mouth—Lisinopril—coronary artery disease	6.07e-05	0.000364	CcSEcCtD
Dabrafenib—Body temperature increased—Losartan—coronary artery disease	6.05e-05	0.000363	CcSEcCtD
Dabrafenib—Abdominal pain—Losartan—coronary artery disease	6.05e-05	0.000363	CcSEcCtD
Dabrafenib—Asthenia—Captopril—coronary artery disease	6.03e-05	0.000362	CcSEcCtD
Dabrafenib—Diarrhoea—Trandolapril—coronary artery disease	6.02e-05	0.000361	CcSEcCtD
Dabrafenib—Vomiting—Valsartan—coronary artery disease	6.02e-05	0.000361	CcSEcCtD
Dabrafenib—Diarrhoea—Enalapril—coronary artery disease	5.99e-05	0.00036	CcSEcCtD
Dabrafenib—Hypotension—Timolol—coronary artery disease	5.99e-05	0.00036	CcSEcCtD
Dabrafenib—Dizziness—Pravastatin—coronary artery disease	5.99e-05	0.000359	CcSEcCtD
Dabrafenib—Vomiting—Olmesartan—coronary artery disease	5.99e-05	0.000359	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Ramipril—coronary artery disease	5.98e-05	0.000359	CcSEcCtD
Dabrafenib—Rash—Valsartan—coronary artery disease	5.97e-05	0.000358	CcSEcCtD
Dabrafenib—Dermatitis—Valsartan—coronary artery disease	5.96e-05	0.000358	CcSEcCtD
Dabrafenib—Nausea—Simvastatin—coronary artery disease	5.95e-05	0.000357	CcSEcCtD
Dabrafenib—Oedema—Lisinopril—coronary artery disease	5.95e-05	0.000357	CcSEcCtD
Dabrafenib—Pruritus—Captopril—coronary artery disease	5.94e-05	0.000357	CcSEcCtD
Dabrafenib—Rash—Olmesartan—coronary artery disease	5.94e-05	0.000356	CcSEcCtD
Dabrafenib—Insomnia—Ramipril—coronary artery disease	5.93e-05	0.000356	CcSEcCtD
Dabrafenib—Dermatitis—Olmesartan—coronary artery disease	5.93e-05	0.000356	CcSEcCtD
Dabrafenib—Headache—Valsartan—coronary artery disease	5.93e-05	0.000356	CcSEcCtD
Dabrafenib—Diarrhoea—Telmisartan—coronary artery disease	5.91e-05	0.000355	CcSEcCtD
Dabrafenib—Infection—Lisinopril—coronary artery disease	5.91e-05	0.000355	CcSEcCtD
Dabrafenib—Headache—Olmesartan—coronary artery disease	5.9e-05	0.000354	CcSEcCtD
Dabrafenib—Asthenia—Perindopril—coronary artery disease	5.85e-05	0.000351	CcSEcCtD
Dabrafenib—Vomiting—Niacin—coronary artery disease	5.85e-05	0.000351	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Timolol—coronary artery disease	5.84e-05	0.000351	CcSEcCtD
Dabrafenib—Hypersensitivity—Furosemide—coronary artery disease	5.84e-05	0.000351	CcSEcCtD
Dabrafenib—Thrombocytopenia—Lisinopril—coronary artery disease	5.83e-05	0.00035	CcSEcCtD
Dabrafenib—Dizziness—Trandolapril—coronary artery disease	5.82e-05	0.000349	CcSEcCtD
Dabrafenib—Insomnia—Timolol—coronary artery disease	5.8e-05	0.000348	CcSEcCtD
Dabrafenib—Rash—Niacin—coronary artery disease	5.8e-05	0.000348	CcSEcCtD
Dabrafenib—Dermatitis—Niacin—coronary artery disease	5.8e-05	0.000348	CcSEcCtD
Dabrafenib—Dizziness—Enalapril—coronary artery disease	5.79e-05	0.000348	CcSEcCtD
Dabrafenib—Skin disorder—Lisinopril—coronary artery disease	5.78e-05	0.000347	CcSEcCtD
Dabrafenib—Pruritus—Perindopril—coronary artery disease	5.77e-05	0.000346	CcSEcCtD
Dabrafenib—Headache—Niacin—coronary artery disease	5.76e-05	0.000346	CcSEcCtD
Dabrafenib—Vomiting—Pravastatin—coronary artery disease	5.76e-05	0.000346	CcSEcCtD
Dabrafenib—Hyperhidrosis—Lisinopril—coronary artery disease	5.75e-05	0.000345	CcSEcCtD
Dabrafenib—Diarrhoea—Captopril—coronary artery disease	5.75e-05	0.000345	CcSEcCtD
Dabrafenib—Dizziness—Telmisartan—coronary artery disease	5.71e-05	0.000343	CcSEcCtD
Dabrafenib—Rash—Pravastatin—coronary artery disease	5.71e-05	0.000343	CcSEcCtD
Dabrafenib—Dermatitis—Pravastatin—coronary artery disease	5.71e-05	0.000342	CcSEcCtD
Dabrafenib—Decreased appetite—Ramipril—coronary artery disease	5.7e-05	0.000342	CcSEcCtD
Dabrafenib—Asthenia—Furosemide—coronary artery disease	5.69e-05	0.000341	CcSEcCtD
Dabrafenib—Headache—Pravastatin—coronary artery disease	5.67e-05	0.00034	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Ramipril—coronary artery disease	5.66e-05	0.00034	CcSEcCtD
Dabrafenib—Fatigue—Ramipril—coronary artery disease	5.66e-05	0.000339	CcSEcCtD
Dabrafenib—Hypersensitivity—Losartan—coronary artery disease	5.64e-05	0.000338	CcSEcCtD
Dabrafenib—Nausea—Valsartan—coronary artery disease	5.62e-05	0.000337	CcSEcCtD
Dabrafenib—Pruritus—Furosemide—coronary artery disease	5.61e-05	0.000337	CcSEcCtD
Dabrafenib—Constipation—Ramipril—coronary artery disease	5.61e-05	0.000337	CcSEcCtD
Dabrafenib—Nausea—Olmesartan—coronary artery disease	5.59e-05	0.000336	CcSEcCtD
Dabrafenib—Vomiting—Trandolapril—coronary artery disease	5.59e-05	0.000336	CcSEcCtD
Dabrafenib—Diarrhoea—Perindopril—coronary artery disease	5.58e-05	0.000335	CcSEcCtD
Dabrafenib—Decreased appetite—Timolol—coronary artery disease	5.58e-05	0.000335	CcSEcCtD
Dabrafenib—Vomiting—Enalapril—coronary artery disease	5.57e-05	0.000334	CcSEcCtD
Dabrafenib—Hypotension—Lisinopril—coronary artery disease	5.56e-05	0.000334	CcSEcCtD
Dabrafenib—Dizziness—Captopril—coronary artery disease	5.56e-05	0.000333	CcSEcCtD
Dabrafenib—Rash—Trandolapril—coronary artery disease	5.55e-05	0.000333	CcSEcCtD
Dabrafenib—Dermatitis—Trandolapril—coronary artery disease	5.54e-05	0.000332	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Timolol—coronary artery disease	5.54e-05	0.000332	CcSEcCtD
Dabrafenib—Fatigue—Timolol—coronary artery disease	5.53e-05	0.000332	CcSEcCtD
Dabrafenib—Rash—Enalapril—coronary artery disease	5.52e-05	0.000331	CcSEcCtD
Dabrafenib—Dermatitis—Enalapril—coronary artery disease	5.52e-05	0.000331	CcSEcCtD
Dabrafenib—Headache—Trandolapril—coronary artery disease	5.51e-05	0.000331	CcSEcCtD
Dabrafenib—Vomiting—Telmisartan—coronary artery disease	5.49e-05	0.00033	CcSEcCtD
Dabrafenib—Asthenia—Losartan—coronary artery disease	5.49e-05	0.000329	CcSEcCtD
Dabrafenib—Headache—Enalapril—coronary artery disease	5.49e-05	0.000329	CcSEcCtD
Dabrafenib—Nausea—Niacin—coronary artery disease	5.46e-05	0.000328	CcSEcCtD
Dabrafenib—Rash—Telmisartan—coronary artery disease	5.45e-05	0.000327	CcSEcCtD
Dabrafenib—Dermatitis—Telmisartan—coronary artery disease	5.44e-05	0.000327	CcSEcCtD
Dabrafenib—Diarrhoea—Furosemide—coronary artery disease	5.43e-05	0.000326	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Lisinopril—coronary artery disease	5.42e-05	0.000325	CcSEcCtD
Dabrafenib—Pruritus—Losartan—coronary artery disease	5.41e-05	0.000325	CcSEcCtD
Dabrafenib—Headache—Telmisartan—coronary artery disease	5.41e-05	0.000325	CcSEcCtD
Dabrafenib—Dizziness—Perindopril—coronary artery disease	5.39e-05	0.000324	CcSEcCtD
Dabrafenib—Insomnia—Lisinopril—coronary artery disease	5.38e-05	0.000323	CcSEcCtD
Dabrafenib—Nausea—Pravastatin—coronary artery disease	5.38e-05	0.000323	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Ramipril—coronary artery disease	5.37e-05	0.000322	CcSEcCtD
Dabrafenib—Vomiting—Captopril—coronary artery disease	5.34e-05	0.000321	CcSEcCtD
Dabrafenib—Rash—Captopril—coronary artery disease	5.3e-05	0.000318	CcSEcCtD
Dabrafenib—Dermatitis—Captopril—coronary artery disease	5.29e-05	0.000318	CcSEcCtD
Dabrafenib—Headache—Captopril—coronary artery disease	5.26e-05	0.000316	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Timolol—coronary artery disease	5.25e-05	0.000315	CcSEcCtD
Dabrafenib—Dizziness—Furosemide—coronary artery disease	5.24e-05	0.000315	CcSEcCtD
Dabrafenib—Diarrhoea—Losartan—coronary artery disease	5.24e-05	0.000314	CcSEcCtD
Dabrafenib—Nausea—Trandolapril—coronary artery disease	5.22e-05	0.000313	CcSEcCtD
Dabrafenib—Nausea—Enalapril—coronary artery disease	5.2e-05	0.000312	CcSEcCtD
Dabrafenib—Vomiting—Perindopril—coronary artery disease	5.19e-05	0.000311	CcSEcCtD
Dabrafenib—Abdominal pain—Ramipril—coronary artery disease	5.19e-05	0.000311	CcSEcCtD
Dabrafenib—Body temperature increased—Ramipril—coronary artery disease	5.19e-05	0.000311	CcSEcCtD
Dabrafenib—Decreased appetite—Lisinopril—coronary artery disease	5.17e-05	0.00031	CcSEcCtD
Dabrafenib—Rash—Perindopril—coronary artery disease	5.14e-05	0.000309	CcSEcCtD
Dabrafenib—Dermatitis—Perindopril—coronary artery disease	5.14e-05	0.000308	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Lisinopril—coronary artery disease	5.14e-05	0.000308	CcSEcCtD
Dabrafenib—Nausea—Telmisartan—coronary artery disease	5.13e-05	0.000308	CcSEcCtD
Dabrafenib—Fatigue—Lisinopril—coronary artery disease	5.13e-05	0.000308	CcSEcCtD
Dabrafenib—Headache—Perindopril—coronary artery disease	5.11e-05	0.000307	CcSEcCtD
Dabrafenib—Constipation—Lisinopril—coronary artery disease	5.09e-05	0.000305	CcSEcCtD
Dabrafenib—Body temperature increased—Timolol—coronary artery disease	5.07e-05	0.000304	CcSEcCtD
Dabrafenib—Abdominal pain—Timolol—coronary artery disease	5.07e-05	0.000304	CcSEcCtD
Dabrafenib—Dizziness—Losartan—coronary artery disease	5.06e-05	0.000304	CcSEcCtD
Dabrafenib—Vomiting—Furosemide—coronary artery disease	5.04e-05	0.000303	CcSEcCtD
Dabrafenib—Rash—Furosemide—coronary artery disease	5e-05	0.0003	CcSEcCtD
Dabrafenib—Dermatitis—Furosemide—coronary artery disease	5e-05	0.0003	CcSEcCtD
Dabrafenib—Nausea—Captopril—coronary artery disease	4.99e-05	0.000299	CcSEcCtD
Dabrafenib—Headache—Furosemide—coronary artery disease	4.97e-05	0.000298	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Lisinopril—coronary artery disease	4.87e-05	0.000292	CcSEcCtD
Dabrafenib—Vomiting—Losartan—coronary artery disease	4.87e-05	0.000292	CcSEcCtD
Dabrafenib—Nausea—Perindopril—coronary artery disease	4.85e-05	0.000291	CcSEcCtD
Dabrafenib—Hypersensitivity—Ramipril—coronary artery disease	4.83e-05	0.00029	CcSEcCtD
Dabrafenib—Rash—Losartan—coronary artery disease	4.82e-05	0.000289	CcSEcCtD
Dabrafenib—Dermatitis—Losartan—coronary artery disease	4.82e-05	0.000289	CcSEcCtD
Dabrafenib—Headache—Losartan—coronary artery disease	4.79e-05	0.000288	CcSEcCtD
Dabrafenib—Hypersensitivity—Timolol—coronary artery disease	4.73e-05	0.000284	CcSEcCtD
Dabrafenib—Nausea—Furosemide—coronary artery disease	4.71e-05	0.000283	CcSEcCtD
Dabrafenib—Asthenia—Ramipril—coronary artery disease	4.71e-05	0.000282	CcSEcCtD
Dabrafenib—Body temperature increased—Lisinopril—coronary artery disease	4.7e-05	0.000282	CcSEcCtD
Dabrafenib—Abdominal pain—Lisinopril—coronary artery disease	4.7e-05	0.000282	CcSEcCtD
Dabrafenib—Pruritus—Ramipril—coronary artery disease	4.64e-05	0.000279	CcSEcCtD
Dabrafenib—Asthenia—Timolol—coronary artery disease	4.6e-05	0.000276	CcSEcCtD
Dabrafenib—Nausea—Losartan—coronary artery disease	4.55e-05	0.000273	CcSEcCtD
Dabrafenib—Pruritus—Timolol—coronary artery disease	4.54e-05	0.000272	CcSEcCtD
Dabrafenib—Diarrhoea—Ramipril—coronary artery disease	4.49e-05	0.000269	CcSEcCtD
Dabrafenib—Diarrhoea—Timolol—coronary artery disease	4.39e-05	0.000263	CcSEcCtD
Dabrafenib—Hypersensitivity—Lisinopril—coronary artery disease	4.38e-05	0.000263	CcSEcCtD
Dabrafenib—Dizziness—Ramipril—coronary artery disease	4.34e-05	0.00026	CcSEcCtD
Dabrafenib—Asthenia—Lisinopril—coronary artery disease	4.27e-05	0.000256	CcSEcCtD
Dabrafenib—Dizziness—Timolol—coronary artery disease	4.24e-05	0.000255	CcSEcCtD
Dabrafenib—Pruritus—Lisinopril—coronary artery disease	4.21e-05	0.000253	CcSEcCtD
Dabrafenib—Vomiting—Ramipril—coronary artery disease	4.17e-05	0.00025	CcSEcCtD
Dabrafenib—Rash—Ramipril—coronary artery disease	4.14e-05	0.000248	CcSEcCtD
Dabrafenib—Dermatitis—Ramipril—coronary artery disease	4.13e-05	0.000248	CcSEcCtD
Dabrafenib—Headache—Ramipril—coronary artery disease	4.11e-05	0.000247	CcSEcCtD
Dabrafenib—Vomiting—Timolol—coronary artery disease	4.08e-05	0.000245	CcSEcCtD
Dabrafenib—Diarrhoea—Lisinopril—coronary artery disease	4.07e-05	0.000244	CcSEcCtD
Dabrafenib—Rash—Timolol—coronary artery disease	4.04e-05	0.000243	CcSEcCtD
Dabrafenib—Dermatitis—Timolol—coronary artery disease	4.04e-05	0.000242	CcSEcCtD
Dabrafenib—Headache—Timolol—coronary artery disease	4.02e-05	0.000241	CcSEcCtD
Dabrafenib—Dizziness—Lisinopril—coronary artery disease	3.94e-05	0.000236	CcSEcCtD
Dabrafenib—Nausea—Ramipril—coronary artery disease	3.9e-05	0.000234	CcSEcCtD
Dabrafenib—Nausea—Timolol—coronary artery disease	3.81e-05	0.000229	CcSEcCtD
Dabrafenib—Vomiting—Lisinopril—coronary artery disease	3.78e-05	0.000227	CcSEcCtD
Dabrafenib—Rash—Lisinopril—coronary artery disease	3.75e-05	0.000225	CcSEcCtD
Dabrafenib—Dermatitis—Lisinopril—coronary artery disease	3.75e-05	0.000225	CcSEcCtD
Dabrafenib—Headache—Lisinopril—coronary artery disease	3.73e-05	0.000224	CcSEcCtD
Dabrafenib—Nausea—Lisinopril—coronary artery disease	3.53e-05	0.000212	CcSEcCtD
Dabrafenib—RAF1—Immune System—JAK2—coronary artery disease	2.85e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—coronary artery disease	2.85e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—coronary artery disease	2.84e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SERPINE1—coronary artery disease	2.84e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—coronary artery disease	2.83e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—coronary artery disease	2.83e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PPP2CA—coronary artery disease	2.83e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2—coronary artery disease	2.82e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CTGF—coronary artery disease	2.82e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOA1—coronary artery disease	2.82e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMGCR—coronary artery disease	2.79e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GOT2—coronary artery disease	2.79e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3C2A—coronary artery disease	2.79e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LIPC—coronary artery disease	2.79e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2C19—coronary artery disease	2.79e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HBA1—coronary artery disease	2.79e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCD—coronary artery disease	2.78e-06	2.12e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF2—coronary artery disease	2.78e-06	2.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOC3—coronary artery disease	2.77e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LDLR—coronary artery disease	2.76e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF2—coronary artery disease	2.74e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—coronary artery disease	2.74e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC27A1—coronary artery disease	2.74e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTT1—coronary artery disease	2.72e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC9A1—coronary artery disease	2.72e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2A—coronary artery disease	2.72e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—coronary artery disease	2.72e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—C3—coronary artery disease	2.72e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—coronary artery disease	2.71e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	2.7e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AGT—coronary artery disease	2.69e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GCLC—coronary artery disease	2.69e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CETP—coronary artery disease	2.69e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CPT1B—coronary artery disease	2.68e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LCAT—coronary artery disease	2.68e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JAK2—coronary artery disease	2.66e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SDC1—coronary artery disease	2.66e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—coronary artery disease	2.64e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—coronary artery disease	2.64e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA4—coronary artery disease	2.63e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—JAK2—coronary artery disease	2.63e-06	2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—coronary artery disease	2.62e-06	2e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOA1—coronary artery disease	2.61e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—coronary artery disease	2.59e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—coronary artery disease	2.59e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGT—coronary artery disease	2.58e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—coronary artery disease	2.57e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLCB1—coronary artery disease	2.57e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PDHA1—coronary artery disease	2.54e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCLM—coronary artery disease	2.54e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK1—coronary artery disease	2.54e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—coronary artery disease	2.53e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—coronary artery disease	2.53e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	2.52e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSMB5—coronary artery disease	2.51e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSMA6—coronary artery disease	2.51e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—coronary artery disease	2.51e-06	1.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOA1—coronary artery disease	2.5e-06	1.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—coronary artery disease	2.49e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCA1—coronary artery disease	2.49e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—coronary artery disease	2.48e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—coronary artery disease	2.48e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—coronary artery disease	2.48e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP11B2—coronary artery disease	2.46e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TXNRD1—coronary artery disease	2.46e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK14—coronary artery disease	2.46e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CTGF—coronary artery disease	2.46e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—coronary artery disease	2.45e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GOT2—coronary artery disease	2.43e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMGCR—coronary artery disease	2.43e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—coronary artery disease	2.43e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC22A3—coronary artery disease	2.43e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—coronary artery disease	2.42e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GOT1—coronary artery disease	2.41e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GGT1—coronary artery disease	2.41e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ARNTL—coronary artery disease	2.39e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HADH—coronary artery disease	2.39e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—coronary artery disease	2.39e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—F2—coronary artery disease	2.39e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FN1—coronary artery disease	2.39e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6ST—coronary artery disease	2.38e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKBIA—coronary artery disease	2.36e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—coronary artery disease	2.33e-06	1.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—coronary artery disease	2.31e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—coronary artery disease	2.3e-06	1.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—coronary artery disease	2.28e-06	1.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA2—coronary artery disease	2.27e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX2—coronary artery disease	2.27e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G2A—coronary artery disease	2.27e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—coronary artery disease	2.27e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—coronary artery disease	2.26e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG5—coronary artery disease	2.24e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX4—coronary artery disease	2.24e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SULT1A1—coronary artery disease	2.24e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HK1—coronary artery disease	2.24e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLCB1—coronary artery disease	2.24e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—coronary artery disease	2.23e-06	1.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—coronary artery disease	2.22e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HADHA—coronary artery disease	2.21e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—coronary artery disease	2.2e-06	1.68e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—coronary artery disease	2.2e-06	1.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GSK3B—coronary artery disease	2.19e-06	1.67e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA1—coronary artery disease	2.19e-06	1.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—coronary artery disease	2.17e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREB1—coronary artery disease	2.17e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ABCA1—coronary artery disease	2.17e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—coronary artery disease	2.17e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPA—coronary artery disease	2.16e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARGC1A—coronary artery disease	2.15e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—coronary artery disease	2.14e-06	1.63e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—coronary artery disease	2.14e-06	1.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—coronary artery disease	2.13e-06	1.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6R—coronary artery disease	2.12e-06	1.62e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAT—coronary artery disease	2.11e-06	1.61e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GGT1—coronary artery disease	2.1e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GOT1—coronary artery disease	2.1e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLCB3—coronary artery disease	2.1e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—coronary artery disease	2.09e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK1—coronary artery disease	2.08e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA5—coronary artery disease	2.07e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—coronary artery disease	2.07e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOB—coronary artery disease	2.05e-06	1.56e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—P4HB—coronary artery disease	2.03e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	2e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—coronary artery disease	1.99e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—coronary artery disease	1.99e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—coronary artery disease	1.98e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—coronary artery disease	1.97e-06	1.5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LPL—coronary artery disease	1.95e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—coronary artery disease	1.95e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—coronary artery disease	1.95e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF2—coronary artery disease	1.92e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—coronary artery disease	1.91e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK1—coronary artery disease	1.9e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—coronary artery disease	1.9e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—coronary artery disease	1.89e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—VCAN—coronary artery disease	1.88e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARGC1A—coronary artery disease	1.87e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDOA—coronary artery disease	1.87e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—coronary artery disease	1.86e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD36—coronary artery disease	1.86e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JAK2—coronary artery disease	1.84e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAT—coronary artery disease	1.84e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPP2CA—coronary artery disease	1.83e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DCN—coronary artery disease	1.81e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—coronary artery disease	1.81e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—coronary artery disease	1.81e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—coronary artery disease	1.81e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—coronary artery disease	1.8e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—coronary artery disease	1.79e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—coronary artery disease	1.79e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOB—coronary artery disease	1.78e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK1—coronary artery disease	1.78e-06	1.35e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDH2—coronary artery disease	1.76e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—coronary artery disease	1.76e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK1—coronary artery disease	1.76e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—coronary artery disease	1.73e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LIPC—coronary artery disease	1.72e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HBA1—coronary artery disease	1.72e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	1.72e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	1.72e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOC3—coronary artery disease	1.71e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LPL—coronary artery disease	1.7e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LDLR—coronary artery disease	1.7e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—coronary artery disease	1.68e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—coronary artery disease	1.68e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	1.68e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGT—coronary artery disease	1.67e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—coronary artery disease	1.66e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCLC—coronary artery disease	1.66e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CETP—coronary artery disease	1.66e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—coronary artery disease	1.65e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SDC1—coronary artery disease	1.64e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—coronary artery disease	1.64e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOA1—coronary artery disease	1.62e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD36—coronary artery disease	1.62e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—coronary artery disease	1.61e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—coronary artery disease	1.6e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPP2CA—coronary artery disease	1.6e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—coronary artery disease	1.57e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.55e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSMB5—coronary artery disease	1.55e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSMA6—coronary artery disease	1.55e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—coronary artery disease	1.54e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—coronary artery disease	1.53e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—coronary artery disease	1.52e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—coronary artery disease	1.52e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CTGF—coronary artery disease	1.51e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMGCR—coronary artery disease	1.5e-06	1.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GOT2—coronary artery disease	1.5e-06	1.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—coronary artery disease	1.47e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—coronary artery disease	1.46e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—coronary artery disease	1.46e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGT—coronary artery disease	1.46e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—coronary artery disease	1.43e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—coronary artery disease	1.43e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOA1—coronary artery disease	1.41e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—coronary artery disease	1.41e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLCB1—coronary artery disease	1.38e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—coronary artery disease	1.37e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—coronary artery disease	1.37e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—coronary artery disease	1.35e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—coronary artery disease	1.35e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCA1—coronary artery disease	1.34e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GOT1—coronary artery disease	1.29e-06	9.86e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GGT1—coronary artery disease	1.29e-06	9.86e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—coronary artery disease	1.28e-06	9.78e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—coronary artery disease	1.26e-06	9.6e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—coronary artery disease	1.25e-06	9.55e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—coronary artery disease	1.24e-06	9.48e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—coronary artery disease	1.24e-06	9.47e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK1—coronary artery disease	1.23e-06	9.37e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—coronary artery disease	1.23e-06	9.35e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—coronary artery disease	1.23e-06	9.34e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—coronary artery disease	1.2e-06	9.16e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—coronary artery disease	1.16e-06	8.86e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	1.15e-06	8.78e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—coronary artery disease	1.15e-06	8.74e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAT—coronary artery disease	1.13e-06	8.62e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—coronary artery disease	1.12e-06	8.55e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—coronary artery disease	1.12e-06	8.52e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—coronary artery disease	1.11e-06	8.48e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOB—coronary artery disease	1.1e-06	8.37e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—coronary artery disease	1.07e-06	8.15e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—coronary artery disease	1.07e-06	8.14e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—coronary artery disease	1.07e-06	8.13e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPL—coronary artery disease	1.05e-06	7.99e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—coronary artery disease	1.02e-06	7.8e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD36—coronary artery disease	9.97e-07	7.59e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	9.84e-07	7.5e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—coronary artery disease	9.82e-07	7.48e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—coronary artery disease	9.78e-07	7.45e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—coronary artery disease	9.44e-07	7.2e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—coronary artery disease	9.44e-07	7.2e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—coronary artery disease	9.09e-07	6.93e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGT—coronary artery disease	8.97e-07	6.84e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—coronary artery disease	8.79e-07	6.7e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—coronary artery disease	8.71e-07	6.64e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA1—coronary artery disease	8.69e-07	6.62e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—coronary artery disease	7.66e-07	5.84e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—coronary artery disease	7.55e-07	5.76e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—coronary artery disease	6.9e-07	5.26e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—coronary artery disease	6.89e-07	5.25e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—coronary artery disease	6.59e-07	5.02e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—coronary artery disease	6.02e-07	4.59e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—coronary artery disease	6.02e-07	4.58e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—coronary artery disease	5.64e-07	4.3e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—coronary artery disease	4.91e-07	3.74e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	3.71e-07	2.82e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—coronary artery disease	3.03e-07	2.31e-06	CbGpPWpGaD
